PMPRB launches consultation on revised Draft Guidelines
Pharma in Brief
JUNE 21, 2020
Medicines with an annual treatment cost >150% of GDP/capita or maximum expected market size >$50 M will be classified as Category I, except biosimilars and generics. Medicines falling below these thresholds, as well as biosimilars and generics, will be classified as Category II.
40 
Let's personalize your content